GSK Plc (GSK)
50.46
-0.18
(-0.35%)
USD |
NYSE |
Nov 13, 16:00
50.46
0.00 (0.00%)
After-Hours: 18:10
GSK Enterprise Value : 128.54B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 128.54B |
| November 11, 2026 | 128.46B |
| November 10, 2026 | 129.72B |
| November 09, 2026 | 130.34B |
| November 06, 2026 | 127.92B |
| November 05, 2026 | 128.08B |
| November 04, 2026 | 129.56B |
| November 03, 2026 | 124.65B |
| November 02, 2026 | 125.51B |
| October 30, 2026 | 126.27B |
| October 29, 2026 | 124.61B |
| October 28, 2026 | 124.73B |
| October 27, 2026 | 129.14B |
| October 26, 2026 | 129.46B |
| October 23, 2026 | 128.76B |
| October 22, 2026 | 129.68B |
| October 21, 2026 | 127.30B |
| October 20, 2026 | 128.52B |
| October 19, 2026 | 126.17B |
| October 16, 2026 | 126.27B |
| October 15, 2026 | 125.29B |
| October 14, 2026 | 122.99B |
| October 13, 2026 | 119.78B |
| October 12, 2026 | 121.08B |
| October 09, 2026 | 120.24B |
| Date | Value |
|---|---|
| October 08, 2026 | 120.32B |
| October 07, 2026 | 121.28B |
| October 06, 2026 | 120.44B |
| October 05, 2026 | 120.34B |
| October 02, 2026 | 121.30B |
| October 01, 2026 | 121.60B |
| September 30, 2026 | 123.59B |
| September 29, 2026 | 119.28B |
| September 28, 2026 | 119.99B |
| September 25, 2026 | 119.06B |
| September 24, 2026 | 119.89B |
| September 23, 2026 | 120.01B |
| September 22, 2026 | 122.05B |
| September 21, 2026 | 122.78B |
| September 18, 2026 | 121.04B |
| September 17, 2026 | 122.74B |
| September 16, 2026 | 121.18B |
| September 15, 2026 | 120.62B |
| September 14, 2026 | 120.70B |
| September 11, 2026 | 116.82B |
| September 10, 2026 | 116.79B |
| September 09, 2026 | 117.83B |
| September 08, 2026 | 117.64B |
| September 04, 2026 | 120.38B |
| September 03, 2026 | 122.36B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 598.18B |
| Johnson & Johnson | 709.89B |
| Eli Lilly & Co. | 1.388T |
| Merck & Co., Inc. | 406.57B |
| Novo Nordisk A/S | 149.40B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.289B |
| Revenue (Quarterly) | 11.94B |
| Total Expenses (Quarterly) | 9.870B |
| EPS Diluted (Quarterly) | 1.018 |
| Gross Profit Margin (Quarterly) | 74.46% |
| Profit Margin (Quarterly) | 19.16% |
| Earnings Yield | 5.68% |
| Operating Earnings Yield | 10.82% |
| Normalized Earnings Yield | 9.008 |